The incremental cost-effectiveness ratio associated with insulin pumps for different HbA1c reductions (for all adults with type 1 diabetes mellitus) and annualised prices of insulin pumps and insulin pump consumables
| 3.3 mmol/mol (0.3%) | 4.4 mmol/mol (0.4%) | 5.5 mmol/mol (0.5%) | 6.6 mmol/mol (0.6%) | 7.7 mmol/mol (0.7%) | 8.7 mmol/mol (0.8%) | 9.8 mmol/mol (0.9%) | 10.9 mmol/mol (1.0%) | 12.0 mmol/mol (1.1%) | 13.1 mmol/mol (1.2%) | |
| £2060 (100%) | £75 710 | £85 990 | £64 493 | £47 667 | £34 280 | £27 951 | £25 979 | £26 258 | £18 953 | £17 610 |
| £1957 (95%) | £69 830 | £79 106 | £58 901 | £43 527 | £31 132 | £25 128 | £23 494 | £23 736 | £16 730 | £15 515 |
| £1854 (90%) | £63 950 | £72 222 | £53 309 | £39 387 | £27 985 | £22 306 | £21 009 | £21 213 | £14 507 | £13 419 |
| £1751 (85%) | £58 070 | £65 338 | £47 717 | £35 247 | £24 837 | £19 483 | £18 524 | £18 691 | £12 284 | £11 323 |
| £1648 (80%) | £52 189 | £58 454 | £42 125 | £31 107 | £21 689 | £16 661 | £16 039 | £16 169 | £10 060 | £9227 |
| £1545 (75%) | £46 309 | £51 570 | £36 533 | £26 967 | £18 542 | £13 838 | £13 554 | £13 646 | £7837 | £7131 |
| £1442 (70%) | £40 429 | £44 686 | £30 941 | £22 827 | £15 394 | £11 016 | £11 070 | £11 124 | £5614 | £5036 |
| £1339 (65%) | £34 549 | £37 802 | £25 349 | £18 687 | £12 246 | £8193 | £8585 | £8602 | £3391 | £2940 |
| £1236 (60%) | £28 668 | £30 917 | £19 757 | £14 547 | £9099 | £5370 | £6100 | £6079 | £1167 | £844 |
| £1133 (55%) | £22 788 | £24 033 | £14 164 | £10 407 | £5951 | £2548 | £3615 | £3557 | Dominates | Dominates |
| £1030 (50%) | £16 908 | £17 149 | £8572 | £6267 | £2803 | Dominates | £1130 | £1035 | Dominates | Dominates |
Red, the incremental cost-effectiveness ratio is above £30,000 per quality adjusted life year gained; Orange, the incremental cost-effectiveness ratio is between £30 000 and £20 000 per quality adjusted life year gained; Green, the incremental cost-effectiveness ratio is less than £20 000 per quality adjusted life year gained.